ClinicalTrials.gg
RecruitingNCT07699991Updated Oct 23, 2026

A Navigation Program to Improve Survivorship Support Service Participation Among Non-metastatic Breast Cancer Survivors

An interventional study of Best Practice and Patient Navigation in Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8 and Anatomic Stage II Breast Cancer AJCC v8, sponsored by Ohio State University Comprehensive Cancer Center. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Ohio State University Comprehensive Cancer Center · Not applicable, Interventional, and Supportive care

How we know

Updated Oct 23, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
330
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Breast Carcinoma In Situ by Ohio State University Comprehensive Cancer Center — 2 open to participants now, 3 under way, none of them phase 3. Breast Carcinoma In Situ · Ohio State University Comprehensive Cancer Center.

Planned enrollment
2nd of 10
330 · median 50
Started
2026
the only one that year
No phase
9 of 11
1 open now
Registered
11th of 11
by date

Among the 11 studies in Breast Carcinoma In Situ by Ohio State University Comprehensive Cancer Center, this one is the 2nd largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2026, is one of 9 with no phase, and was the 11th registered.

Breast Carcinoma In Situ

190 studies on the registry are indexed under Breast Carcinoma In Situ; 25 are open to participants now.

Browse Breast Carcinoma In Situ studies →

Open to participants now

2 of the 11 studies in Breast Carcinoma In Situ by Ohio State University Comprehensive Cancer Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 23 Breast Carcinoma In Situ studies recruiting now, 17 (74%) set no upper age limit and 4 (17%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Breast Carcinoma In Situ by Ohio State University Comprehensive Cancer Center, or all of them as a file.
02

Study summary

This clinical trial studies whether a navigation program improves survivorship support service participation among survivors of breast cancer that has not spread from where it first started (primary site) to other places in the body (non-metastatic). Advances in treatment have caused the number of breast cancer survivors to grow. As this number increases, there are reported unmet supportive care needs in this population, including psychological distress and limitations in physical functioning. To address these needs, many cancer centers offer programming on a variety of topics including psychological services, exercise counseling, and nutrition counseling. Research has shown that while interest in these survivorship programs is high, participation remains low, especially among minority women. Navigation is a healthcare service that is designed to guide a patient through the healthcare system and reduce barriers to timely screening, follow-up, diagnosis, treatment, and supportive care. The navigation program in this trial is specifically focused on helping breast cancer survivors schedule and attend survivorship consultation appointments as well as providing additional support to underserved/vulnerable patients. A navigation program may be effective in improving survivorship support service participation among non-metastatic breast cancer survivors.

Read the detailed description

PRIMARY OBJECTIVES:

I. Increase the rate of referrals to survivorship support services among eligible breast cancer survivors by 50% within 12 months following implementation of a structured navigation program. (Aim 1) II. Reduce the rate of non-scheduled survivorship visits (defined as no appointment made within 30 days of referral) by 50% and increase the re-scheduling success rate among patients who initially cancel. (Aim 2)

SECONDARY OBJECTIVE:

I. Among patients identified as at-risk (minority race/ethnicity, rural residence, age ≥ 70), assess the uptake of coaching, and evaluate changes in self-efficacy scores before and after a 90-day navigation-based coaching intervention. (Aim 3)

OUTLINE:

Patients receive a referral to survivorship at James Cancer Supportive Care Clinic and attend a survivorship consultation visit consisting of standard survivorship care and referrals at baseline. Patients who do not schedule or cancel the survivorship consultation visit receive patient navigator support to help with scheduling. Following survivorship consult, underserved/vulnerable patients may attend five patient navigator coaching sessions over 90 days.

03

Conditions studied

  • Anatomic Stage 0 Breast Cancer AJCC v8
  • Anatomic Stage I Breast Cancer AJCC v8
  • Anatomic Stage II Breast Cancer AJCC v8
  • Anatomic Stage III Breast Cancer AJCC v8
  • Localized Breast Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • GENERAL INCLUSION (PRIMARY OBJECTIVE): Ages 18+
  • GENERAL INCLUSION (PRIMARY OBJECTIVE): Diagnosed with non- breast cancer
  • GENERAL INCLUSION (PRIMARY OBJECTIVE): Received care at Stefanie Spielman Breast Center
  • COACHING INCLUSION (SECONDARY OBJECTIVE): Referred patients who fall under any of the following:

    • Black and/or Hispanic
    • Ages ≥ 70
    • Reside in a ZIP code classified as rural by United States Department of Agriculture (USDA) Rural-Urban Commuting Area (RUCA) codes

Exclusion criteria

Exclusion Criteria:

  • breast cancer at time of referral
  • Prisoners or individuals unable to consent
  • Non-English and non-Spanish speakers
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
330 participants (estimated)

Study arms

  • Experimental
    Supportive care (breast cancer survivor navigation program)

    Patients receive a referral to survivorship at James Cancer Supportive Care Clinic and attend a survivorship consultation visit consisting of standard survivorship care and referrals at baseline. Patients who do not schedule or cancel the survivorship consultation visit receive patient navigator support to help with scheduling. Following survivorship consult, underserved/vulnerable patients may attend five patient navigator coaching sessions over 90 days.

    Other: Best Practice · Behavioral: Patient Navigation · Other: Referral · Other: Survey Administration

Interventions

  • OtherBest Practice

    Attend survivorship consultation

    Also known as: standard of care, standard therapy

  • BehavioralPatient Navigation

    Receive patient navigator scheduling support

    Also known as: Patient Navigator Program

  • BehavioralPatient Navigation

    Attend patient navigator coaching sessions

    Also known as: Patient Navigator Program

  • OtherReferral

    Receive survivorship referral

    Also known as: Referred

  • OtherSurvey Administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Referral rates (Aims 1 & 2)

    Will be tracked for all patients referred to the Survivorship Clinic. Rates will be calculated by dividing the number of events by the total number of eligible patients in each period. Will be compared between baseline and intervention periods using chi-square tests or logistic regression models.

    Time frame: From 12 months prior to intervention (baseline) up to 12 months during the program

  2. Scheduling after referral (Aims 1 & 2)

    Will be tracked for all patients referred to the Survivorship Clinic. Rates will be calculated by dividing the number of events by the total number of eligible patients in each period. Will be compared between baseline and intervention periods using chi-square tests or logistic regression models.

    Time frame: From 12 months prior to intervention (baseline) up to 12 months during the program

  3. Clinic attendance (Aims 1 & 2)

    Will be tracked for all patients referred to the Survivorship Clinic. Rates will be calculated by dividing the number of events by the total number of eligible patients in each period. Will be compared between baseline and intervention periods using chi-square tests or logistic regression models.

    Time frame: From 12 months prior to intervention (baseline) up to 12 months during the program

Secondary outcomes

  1. Proportion of eligible patients who consent and initiate sessions (Acceptance)

    Among patients meeting eligibility criteria (Black, Hispanic, age ≥ 70, rural ZIP code), acceptance of coaching will be measured as the proportion of eligible patients who consent and initiate sessions. Will be analyzed using descriptive statistics and regression models to evaluate predictors of acceptance.

    Time frame: Up to 12 months

  2. Change in patient-reported outcomes (PROMIS-10)

    Patient Reported Outcomes Measurement Information System-10 \[PROMIS-10\] will be collected at baseline and at 90-day follow-up. The PROMIS-10 includes 10 questions that evaluate the participants health related quality of life. Changes in self-efficacy and quality of life will be evaluated within individuals. Changes in PROMIS-10 scores will be assessed using paired t-tests or Wilcoxon signed-rank tests, as appropriate.

    Time frame: Baseline to 90 days

  3. Subgroup referral and uptake patterns

    Analyses will assess whether referral rates, scheduling, coaching uptake, and patient-reported outcomes differ by demographic or clinical subgroups (e.g., age, race, rurality, insurance, education level). Subgroup analyses will employ stratified analyses and regression modeling to identify differences across patient characteristics.

    Time frame: Up to 12 months

  4. Change in patient-reported outcomes (BSES)

    Breast Cancer Survivor Self-Efficacy Scale \[BSES\] will be collected at baseline and at 90-day follow-up. Changes in self-efficacy and quality of life will be evaluated within individuals. Changes in BSES scores will be assessed using paired t-tests or Wilcoxon signed-rank tests, as appropriate.

    Time frame: Baseline to 90 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Related links

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2027, 12 months later.

Of 38 non-industry interventional studies with no phase under Breast Carcinoma In Situ, half reached primary completion within 63 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 128. This study's planned 12 months is below that.

Counting every sponsor, half of 39 studies reached it within 63 months; a quarter within 38 and three quarters within 128.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Dec 2026, on Oct 23, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2026
First posted
Jul 13, 2026
StartEst.
Dec 9, 2026was Sep 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 1, 2026→Dec 9, 2026
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Start date Sep 1, 2026→Dec 9, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07699991
Responsible party
Bridget Oppong (Principal Investigator, Ohio State University Comprehensive Cancer Center) — Principal investigator
First posted
Jul 13, 2026
Start date
Dec 9, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 23, 2026

Study contacts

The Ohio State University Comprehensive Cancer Center
Contact
OSUCCCClinicaltrials@osumc.edu
1-800-293-5066
Bridget A Oppong, MD, MPH
principal investigator · Ohio State University Comprehensive Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion